-Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, announced a collaboration wit...
Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible ...
SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and ...
VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform cutting drug di...
Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a p...
In this BioPharma Boardroom discussion, we speak with Christophe Hotermans, Head of Global Medical Affairs at Alexion, AstraZeneca Rare Disease. From the e...
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch with $50 million of committed capital. Founded to address u...
Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through...
Orchard Therapeutics, a Kyowa Kirin company, announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...
MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a pa...
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, announces that the FDA has granted the Regenerative...
Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disor...
© 2025 Biopharma Boardroom. All Rights Reserved.
